SOX2-RNAi attenuates S-phase entry and induces RhoA-dependent switch to protease-independent amoeboid migration in human glioma cells

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Oppel, Felix ^a   Müller, Nadja ^a   Schackert, Gabriele ^a   Hendruschk, Sandy ^a   Martin, Daniel ^a   Geiger, Kathrin D ^b   Temme, Achim ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN PROTEIN; CYCLIN D1; FOCAL ADHESION KINASE; GELATINASE A; INTERSTITIAL COLLAGENASE; LYMPHOID ENHANCER FACTOR 1; NEDD9 PROTEIN; NESTIN; OCTAMER TRANSCRIPTION FACTOR 4; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SHORT HAIRPIN RNA; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; FOCAL ADHESION KINASE 1; PTK2 PROTEIN, HUMAN; RHOA PROTEIN, HUMAN; SMALL INTERFERING RNA; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CELL CYCLE S PHASE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GLIOMA CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PLEIOTROPY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; XENOGRAFT; ANIMAL; CANCER INVASION; CELL MOTION; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; GLIOMA; METABOLISM; MOUSE STRAIN; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FOCAL ADHESION KINASE 1; GLIOMA; HUMANS; MICE; MICE, INBRED STRAINS; NEOPLASM INVASIVENESS; RHOA GTP-BINDING PROTEIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; S PHASE; SOXB1 TRANSCRIPTION FACTORS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80655132137     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-137     Document Type: Article

References (59)

1. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005, 64:479-489.
2. Pedersen PH, Edvardsen K, Garcia-Cabrera I, Mahesparan R, Thorsen J, Mathisen B, Rosenblum ML, Bjerkvig R. Migratory patterns of lac-z transfected human glioma cells in the rat brain. Int J Cancer 1995, 62:767-771. 10.1002/ijc.2910620620, 7558428.
3. Giese A, Westphal M. Glioma invasion in the central nervous system. Neurosurgery 1996, 39:235-250. 10.1097/00006123-199608000-00001, 8832660.
4. Hou LC, Veeravagu A, Hsu AR, Tse VC. Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus 2006, 20:E5.
5. Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin Oncol 2004, 31:635-644. 10.1053/j.seminoncol.2004.07.005, 15497116.
6. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109. 10.1007/s00401-007-0243-4, 1929165, 17618441.
7. Galderisi U, Cipollaro M, Giordano A. Stem cells and brain cancer. Cell Death Differ 2006, 13:5-11. 10.1038/sj.cdd.4401757, 16123777.
8. Schmitz M, Temme A, Senner V, Ebner R, Schwind S, Stevanovic S, Wehner R, Schackert G, Schackert HK, Fussel M, Bachmann M, Rieber EP, Weigle B. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer 2007, 96:1293-1301. 10.1038/sj.bjc.6603696, 2360145, 17375044.
9. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev 2003, 17:126-140. 10.1101/gad.224503, 195970, 12514105.
10. Ferri AL, Cavallaro M, Braida D, Di CA, Canta A, Vezzani A, Ottolenghi S, Pandolfi PP, Sala M, DeBiasi S, Nicolis SK. Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. Development 2004, 131:3805-3819. 10.1242/dev.01204, 15240551.
11. Pevny LH, Nicolis SK. Sox2 roles in neural stem cells. Int J Biochem Cell Biol 2010, 42:421-424. 10.1016/j.biocel.2009.08.018, 19733254.
12. Graham V, Khudyakov J, Ellis P, Pevny L. SOX2 functions to maintain neural progenitor identity. Neuron 2003, 39:749-765. 10.1016/S0896-6273(03)00497-5, 12948443.
13. Ellis P, Fagan BM, Magness ST, Hutton S, Taranova O, Hayashi S, McMahon A, Rao M, Pevny L. SOX2, a persistent marker for multipotential neural stem cells derived from embryonic stem cells, the embryo or the adult. Dev Neurosci 2004, 26:148-165. 10.1159/000082134, 15711057.
14. Kondo T, Raff M. Chromatin remodeling and histone modification in the conversion of oligodendrocyte precursors to neural stem cells. Genes Dev 2004, 18:2963-2972. 10.1101/gad.309404, 534656, 15574597.
15. Bylund M, Andersson E, Novitch BG, Muhr J. Vertebrate neurogenesis is counteracted by Sox1-3 activity. Nat Neurosci 2003, 6:1162-1168. 10.1038/nn1131, 14517545.
16. Bani-Yaghoub M, Tremblay RG, Lei JX, Zhang D, Zurakowski B, Sandhu JK, Smith B, Ribecco-Lutkiewicz M, Kennedy J, Walker PR, Sikorska M. Role of Sox2 in the development of the mouse neocortex. Dev Biol 2006, 295:52-66. 10.1016/j.ydbio.2006.03.007, 16631155.
17. Wang Q, He W, Lu C, Wang Z, Wang J, Giercksky KE, Nesland JM, Suo Z. Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res 2009, 29:1233-1241.
18. Sanada Y, Yoshida K, Ohara M, Oeda M, Konishi K, Tsutani Y. Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas 2006, 32:164-170. 10.1097/01.mpa.0000202947.80117.a0, 16552336.
19. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, Rodriguez-Gil Y, Martinez MA, Hernandez L, Hardisson D, Reis-Filho JS, Palacios J. Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol 2007, 20:474-481. 10.1038/modpathol.3800760, 17334350.
20. Wilbertz T, Wagner P, Petersen K, Stiedl AC, Scheble VJ, Maier S, Reischl M, Mikut R, Altorki NK, Moch H, Fend F, Staebler A, Bass AJ, Meyerson M, Rubin MA, Soltermann A, Lengerke C, Perner S. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol 2011, 24:944-953. 10.1038/modpathol.2011.49, 21460799.
21. Ge N, Lin HX, Xiao XS, Guo L, Xu HM, Wang X, Jin T, Cai XY, Liang Y, Hu WH, Kang T. Prognostic significance of Oct4 and Sox2 expression in hypopharyngeal squamous cell carcinoma. J Transl Med 2010, 8:94. 10.1186/1479-5876-8-94, 2958910, 20937145.
22. Otsubo T, Akiyama Y, Yanagihara K, Yuasa Y. SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer 2008, 98:824-831. 10.1038/sj.bjc.6604193, 2259184, 18268498.
23. Phi JH, Park SH, Kim SK, Paek SH, Kim JH, Lee YJ, Cho BK, Park CK, Lee DH, Wang KC. Sox2 expression in brain tumors: a reflection of the neuroglial differentiation pathway. Am J Surg Pathol 2008, 32:103-112. 10.1097/PAS.0b013e31812f6ba6, 18162777.
24. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, Ravetti GL, Zona GL, Daga A, Corte G. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 2009, 27:40-48. 10.1634/stemcells.2008-0493, 18948646.
25. Ferletta M, Caglayan D, Mokvist L, Jiang Y, Kastemar M, Uhrbom L, Westermark B. Forced expression of Sox21 inhibits Sox2 and induces apoptosis in human glioma cells. Int J Cancer 2011, 129:45-60. 10.1002/ijc.25647, 20824710.
26. Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, Sun L, Yang X, Wang Y, Zhang Y, Shang Y. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 2008, 283:17969-17978. 10.1074/jbc.M802917200, 18456656.
27. Asai A, Miyagi Y, Sugiyama A, Gamanuma M, Hong SH, Takamoto S, Nomura K, Matsutani M, Takakura K, Kuchino Y. Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy. J Neurooncol 1994, 19:259-268. 10.1007/BF01053280, 7807177.
28. Shono T, Tofilon PJ, Schaefer TS, Parikh D, Liu TJ, Lang FF. Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation. Cancer Res 2002, 62:1069-1076.
29. Basu-Roy U, Seo E, Ramanathapuram L, Rapp TB, Perry JA, Orkin SH, Mansukhani A, Basilico C. Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas. Oncogene 2011,
30. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005, 6:56-68. 10.1038/nrm1549, 15688067.
31. Natarajan M, Stewart JE, Golemis EA, Pugacheva EN, Alexandropoulos K, Cox BD, Wang W, Grammer JR, Gladson CL. HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene 2006, 25:1721-1732. 10.1038/sj.onc.1209199, 16288224.
32. Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol 1994, 14:1680-1688. 358526, 7509446.
33. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, Strongin AY, Brocker EB, Friedl P. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 2003, 160:267-277. 10.1083/jcb.200209006, 2172637, 12527751.
34. Sahai E, Marshall CJ. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol 2003, 5:711-719. 10.1038/ncb1019, 12844144.
35. Charras GT, Hu CK, Coughlin M, Mitchison TJ. Reassembly of contractile actin cortex in cell blebs. J Cell Biol 2006, 175:477-490. 10.1083/jcb.200602085, 2064524, 17088428.
36. Torka R, Thuma F, Herzog V, Kirfel G. ROCK signaling mediates the adoption of different modes of migration and invasion in human mammary epithelial tumor cells. Exp Cell Res 2006, 312:3857-3871. 10.1016/j.yexcr.2006.08.025, 17010335.
37. Herrlich P, Morrison H, Sleeman J, Orian-Rousseau V, Konig H, Weg-Remers S, Ponta H. CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann NY Acad Sci 2000, 910:106-118.
38. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990, 61:1303-1313. 10.1016/0092-8674(90)90694-A, 1694723.
39. Narumiya S, Tanji M, Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev 2009, 28:65-76. 10.1007/s10555-008-9170-7, 19160018.
40. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997, 389:990-994. 10.1038/40187, 9353125.
41. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003, 4:446-456. 10.1038/nrm1128, 12778124.
42. Naito S, Shimizu S, Matsuu M, Nakashima M, Nakayama T, Yamashita S, Sekine I. Ets-1 upregulates matrix metalloproteinase-1 expression through extracellular matrix adhesion in vascular endothelial cells. Biochem Biophys Res Commun 2002, 291:130-138. 10.1006/bbrc.2002.6418, 11829472.
43. Taki M, Verschueren K, Yokoyama K, Nagayama M, Kamata N. Involvement of Ets-1 transcription factor in inducing matrix metalloproteinase-2 expression by epithelial-mesenchymal transition in human squamous carcinoma cells. Int J Oncol 2006, 28:487-496.
44. Fang X, Yoon JG, Li L, Yu W, Shao J, Hua D, Zheng S, Hood L, Goodlett DR, Foltz G, Lin B. The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray: and microRNA analysis. BMC Genomics 2011, 12:11. 10.1186/1471-2164-12-11, 3022822, 21211035.
45. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008, 40:499-507. 10.1038/ng.127, 2912221, 18443585.
46. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003, 3:362-374. 10.1038/nrc1075, 12724734.
47. Paulus W, Baur I, Beutler AS, Reeves SA. Diffuse brain invasion of glioma cells requires beta 1 integrins. Lab Invest 1996, 75:819-826.
48. Knudson W. Tumor-associated hyaluronan. Providing an extracellular matrix that facilitates invasion. Am J Pathol 1996, 148:1721-1726. 1861627, 8669457.
49. Tsukita S, Oishi K, Sato N, Sagara J, Kawai A, Tsukita S. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol 1994, 126:391-401. 10.1083/jcb.126.2.391, 2200023, 7518464.
50. Ruoslahti E. Brain extracellular matrix. Glycobiology 1996, 6:489-492. 10.1093/glycob/6.5.489, 8877368.
51. Li Z, Wang C, Jiao X, Lu Y, Fu M, Quong AA, Dye C, Yang J, Dai M, Ju X, Zhang X, Li A, Burbelo P, Stanley ER, Pestell RG. Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling. Mol Cell Biol 2006, 26:4240-4256. 10.1128/MCB.02124-05, 1489104, 16705174.
52. Jia X, Li X, Xu Y, Zhang S, Mou W, Liu Y, Liu Y, Lv D, Liu CH, Tan X, Xiang R, Li N. SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol 2011, 3:230-238. 10.1093/jmcb/mjr002, 21415100.
53. Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, Pandiella A, Rezola R, Martin AG. Sox2 expression in breast tumours, activation in breast cancer stem cells. Oncogene 2011,
54. Otsubo T, Akiyama Y, Hashimoto Y, Shimada S, Goto K, Yuasa Y. MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis. PLoS One 2011, 6:e16617. 10.1371/journal.pone.0016617, 3029394, 21304604.
55. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002, 26:199-213. 10.1016/S1046-2023(02)00023-3, 12054897.
56. Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM, Kingsman AJ. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 1995, 23:628-633. 10.1093/nar/23.4.628, 306730, 7899083.
57. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005, 21:247-269. 10.1146/annurev.cellbio.21.020604.150721, 16212495.
58. van Nieuw Amerongen GP, Vermeer MA, van V H. Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. Arterioscler Thromb Vasc Biol 2000, 20:E127-E133. 10.1161/01.ATV.20.12.e127, 11116077.
59. Temme A, Geiger KD, Wiedemuth R, Conseur K, Pietsch T, Felsberg J, Reifenberger G, Tatsuka M, Hagel C, Westphal M, Berger H, Simon M, Weller M, Schackert G. Giant cell glioblastoma is associated with altered aurora b expression and concomitant p53 mutation. J Neuropathol Exp Neurol 2010, 69:632-642. 10.1097/NEN.0b013e3181e4c06e, 20467329.